Kronik İnflamatuar Demiyelinizan Polinöropati ve İlişkili Varyantlar

Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst. 2014;19(1):2-13.

Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. Eur J Neurol. 2021;28(11):3556-3583. doi:10.1111/ENE.14959

Sarıkaya Uzan G, Vural A, Yüksel D, et al. Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study. Pediatr Neurol. 2023;145:3-10. doi:10.1016/J.PEDIATRNEUROL.2023.04.018

Desai J, Ramos-Platt L, Mitchell WG. Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions. Ann Indian Acad Neurol. 2015;18(3):327-330. doi:10.4103/0972-2327.160065

Haliloğlu G, Yüksel D, Temoçin CM, Topaloğlu H. Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2016;26(12):817-824. doi:10.1016/J.NMD.2016.09.016

Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001;184(1):57-63. doi:10.1016/S0022-510X(00)00493-7

Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-172. doi:10.1159/000494291

Sotgiu S, Onida I, Magli G, et al. Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy. Neuropediatrics. 2021;52(1):56-61. doi:10.1055/S-0040-1715626

Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66(5):677-680. doi:10.1136/JNNP.66.5.677

Allen JA, Lewis RA. Diagnosis of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2022;66(5):545-551. doi:10.1002/MUS.27708

Rajabally YA, Peric S, Bozovic I, et al. Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study. Muscle Nerve. 2021;64(6):657-661. doi:10.1002/MUS.27374

Kuwabara S, Misawa S. Chronic Inflammatory Demyelinating Polyneuropathy. Adv Exp Med Biol. 2019;1190:333-343. doi:10.1007/978-981-32-9636-7_21

Koike H, Katsuno M. Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. Neurol Ther. 2020;9(2):213-227. doi:10.1007/S40120-020-00190-8

Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2008;38(2):1036-1045. doi:10.1002/MUS.21000

Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46(8):878-884. doi:10.1001/ARCHNEUR.1989.00520440064022

Hughes RAC, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2005;10(3):220-228. doi:10.1111/J.1085-9489.2005.10302.X

Van Den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356-363. doi:10.1111/J.1468-1331.2009.02930.X

Doorn IN va., Eftimov F, Wieske L, Schaik IN va., Verhamme C. Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives. Ther Clin Risk Manag. 2024;20:111-126. doi:10.2147/TCRM.S360249

Lewis R, Jeremy M. Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis. Neurophysiol Clin. 2004;34(2):71-9.e.

Maisonobe T, Chassande B, Vérin M, Jouni M, Léger JM, Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry. 1996;61(1):36-42. doi:10.1136/JNNP.61.1.36

Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90(2):125-132. doi:10.1136/JNNP-2018-318714

Al-Zuhairy A, Sindrup SH, Andersen H, Jakobsen J. A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;61(3):316-324. doi:10.1002/MUS.26772

Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85(6):498-504. doi:10.1212/WNL.0000000000001833

Oaklander AL, Lunn MPT, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane database Syst Rev. 2017;1(1). doi:10.1002/14651858.CD010369.PUB2

Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729-734. doi:10.1136/JNNP-2013-307515

van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245-253. doi:10.1016/S1474-4422(10)70021-1

Eftimov F, Vermeulen M, Van Doorn PA, Brusse E, Van Schaik IN. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012;78(14):1079-1084. doi:10.1212/WNL.0B013E31824E8F84

Burt RK, Tappenden P, Balabanov R, et al. The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP. Front Neurol. 2021;12. doi:10.3389/FNEUR.2021.645263

Kapoor M, Hunt I, Spillane J, et al. IVIg-exposure and thromboembolic event risk: findings from the UK Biobank. J Neurol Neurosurg Psychiatry. 2022;93(8):876-885. doi:10.1136/JNNP-2022-328881

Rabin M, Mutlu G, Stojkovic T, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psychiatry. 2014;85(8):899-904. doi:10.1136/JNNP-2013-306105

Svačina MKR, Meißner A, Schweitzer F, et al. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study. Eur J Neurol. 2024;31(1). doi:10.1111/ENE.16079

Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119 ( Pt 4)(4):1055-1066. doi:10.1093/BRAIN/119.4.1055

Mörtzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: An update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2-15. doi:10.1016/J.TRANSCI.2016.01.003